Clinical and Translational Evidence for BALIMONT, a Lactobacillus acidophilus-Centered Biotic Composition, in Modulating Immune-Inflammatory Responses
Scientific Journal of Technology · 21.04.2026 · 8 (4) · 262-268
DOI: 10.54691/pzavt423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Journal of Technology, online erschienen am 21.04.2026. Verfasst von Anas Ziraoui und 2 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Low-grade inflammation, mucosal-barrier disruption, and recurrent gastrointestinal inflammatory symptoms frequently coexist in adults with immune-inflammatory dysregulation. Multi-strain probiotic systems and postbiotic preparations have both shown anti-inflammatory potential in human studies, but formulation-specific evidence remains essential.
Objective
We aimed to present a evidence paper for the BALIMONT composition by integrating retained formulation benchmark data with available clinical trials and meta-analyses relevant to its strains, postbiotic strategy, biomarker framework, and symptom targets.
Methods
We retained the original composition architecture, comparator logic, core numerical benchmarks, and three source figures from the development dossier. We then searched peer-reviewed public sources up to March 2026 for randomized controlled trials, placebo-controlled trials, pilot studies, and meta-analyses involving Lactobacillus acidophilus, Lactiplantibacillus plantarum, Bifidobacterium longum, probiotics, postbiotics, inflammatory biomarkers, and gastrointestinal symptom outcomes. We prioritized adult human data and outcome measures directly relevant to hs-CRP/CRP, IL-6, TNF-alpha, IL-10, calprotectin, and GI symptom burden.
Results
The retained BALIMONT benchmark program showed a stronger comparator-direction signal for inflammatory suppression and barrier support than the live-bacteria-only reference, including a 68.2% reduction in total serum inflammatory factors and a 42.6% increase in colonic tight-junction protein expression in the lead example, versus 32.5% and 18.3%, respectively, in the comparator framework. Across external human evidence, a meta-analysis of 42 randomized trials reported significant reductions in hs-CRP, TNF-alpha, and IL-6 together with higher IL-10 after probiotic supplementation, while a 2023 umbrella meta-analysis also supported reductions in CRP, TNF-alpha, and IL-6. Strain-relevant clinical studies further showed improvements in bloating with Lactobacillus acidophilus NCFM plus Bifidobacterium lactis Bi-07, decreased inflammatory and lipid-related markers with heat-killed Lactiplantibacillus plantarum L-137 in overweight adults, improved IBS-D symptom severity with both live and heat-treated Bifidobacterium longum CECT 7347, and significant reduction in fecal calprotectin with Lactiplantibacillus plantarum HEAL9 in older adults with chronic low-grade inflammation.
Conclusions
The currently available human evidence supports the anti-inflammatory plausibility of the BALIMONT design and aligns with its retained benchmark endpoints, particularly for CRP-related inflammation, cytokine modulation, GI symptom improvement, and postbiotic-enabled translational relevance. A prospective registered trial remains necessary for direct confirmation of this exact formulation.
Zitieren
APA
Ziraoui, A., Khan, Z., & Valenti, R. (2026). Clinical and Translational Evidence for BALIMONT, a Lactobacillus acidophilus-Centered Biotic Composition, in Modulating Immune-Inflammatory Responses. Scientific Journal of Technology, 8(4), 262-268. https://doi.org/10.54691/pzavt423
Vancouver
Ziraoui A, Khan Z, Valenti R. Clinical and Translational Evidence for BALIMONT, a Lactobacillus acidophilus-Centered Biotic Composition, in Modulating Immune-Inflammatory Responses. Scientific Journal of Technology. 2026;8(4):262-268. doi:10.54691/pzavt423
BibTeX
@article{Ziraoui2026,
author = {Ziraoui, Anas and Khan, Zara and Valenti, Rico},
title = {Clinical and Translational Evidence for BALIMONT, a Lactobacillus acidophilus-Centered Biotic Composition, in Modulating Immune-Inflammatory Responses},
journal = {Scientific Journal of Technology},
year = {2026},
volume = {8},
number = {4},
pages = {262--268},
doi = {10.54691/pzavt423}
}
EUVIMED